Nippon Kayaku, Eiger deal

Nippon granted Eiger rights to develop Bestatin ubenimex for pulmonary arterial hypertension (PAH) and inflammatory diseases that involve leukotriene B4 (LTB4). Nippon markets Bestatin in Japan as a...